11:35 AM - 12:05 PM ET
Avoiding failure: The path to commercial viability for CGTs
The promise of cell and gene therapy (CGT) is immense, yet realizing its full clinical and commercial potential remains out-of-reach for most companies. We have cures for cancer and rare diseases that remain inaccessible because these therapies are complex, costly and difficult to manufacture at scale. Major pharmaceutical companies are exiting the market, promising companies are collapsing and transformative therapies are being abandoned—not due to clinical ineffectiveness, but because the current economic model is broken. This discussion candidly explores these critical issues, highlighting strategies to navigate manufacturing complexities, scalability hurdles, regulatory uncertainties and cost barriers. Attendees will gain actionable insights on how flexible, best of breed approaches can reshape the economic model and ensure life-saving CGT treatments finally reach the patients who need them.